Confronta i metodi

	Valutazione d'impatto controfattuale aumentata dall'apprendimento automatico	Abbinamento del punteggio di propensione
Campo	Inferenza causale	Statistica per la ricerca
Famiglia	Regression model	Process / pipeline
Anno di origine	2016-2019	1983
Ideatore	Chernozhukov et al.; Athey & Imbens	Paul Rosenbaum and Donald Rubin
Tipo	Causal inference / ML-augmented evaluation	Method
Fonte seminale	Chernozhukov, V., Chetverikov, D., Demirer, M., Duflo, E., Hansen, C., Newey, W., & Robins, J. (2018). Double/debiased machine learning for treatment and structural parameters. The Econometrics Journal, 21(1), C1-C68.	Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55.
Alias	ML-augmented counterfactual evaluation, ML-CIE, causal ML impact evaluation, double ML counterfactual evaluation	PSM, propensity score weighting, covariate balance
Correlati	5	3
Sintesi	Machine learning-augmented counterfactual impact evaluation combines the credibility of potential-outcomes causal inference with the flexibility of modern ML algorithms. Rather than imposing parametric functional forms for confounders, ML learners — such as lasso, random forests, or neural nets — estimate nuisance functions (propensity scores, outcome regressions) that are then used to construct approximately unbiased estimates of causal effects. The canonical instantiation is Double/Debiased Machine Learning (DML), formalized by Chernozhukov et al. (2018).	Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias.